SAN DIEGO, May 17, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it received the CLARUS Award presented by MDB Capital Group at the second annual Bright Lights Conference in New York City on May 10th. The Bright Lights Conference is the only conference with an exclusive focus on publicly-traded companies possessing disruptive and market changing IP, providing institutional investors with a venue to discover the largely unrecognized value of embedded IP.
"Verenium was the top company in its industry with the highest Tech Score and number of patent grants, and we are honored to recognize their achievements in driving IP as an asset class and the impact they are making on innovation in America," commented Christopher A. Marlett, CEO of MDB Capital Group.
Verenium's technology was selected from MDB's 2011 group of "Best and Brightest" small-cap companies, a group that is advancing some of today's most innovative and market-leading intellectual property (IP) and advanced as one of the 40 public companies ranking in the 90th percentile for its respective technology leadership from more than 1,500 small-cap companies with granted U.S. patents, as rated by PatentVest, MDB's proprietary IP business intelligence platform. Verenium was recognized for its innovation leadership and achieving the highest Tech Score and number of patent grants.
"We are honored to have received the CLARUS award, further affirmation of the strength of Verenium's intellectual property and core technology platform," said James Levine, President and Chief Executive Officer at Verenium. "Verenium's proven proprietary technology enables the rapid discovery and evolution of uniquely tailored enzymes optimized for performance in challengi
|SOURCE Verenium Corporation|
Copyright©2010 PR Newswire.
All rights reserved